公开(公告)号：US20210252102A1

公开(公告)日：2021-08-19

申请号：US17244883

申请日：2021-04-29

Applicant: The Texas A&M University System ,  The Regents of the University of Colorado, a Body Corporate

Inventor： Richard Tobin ,  Martha Karen Newell-Rogers

IPC: A61K38/08 ,  A61P35/00 ,  C07K16/28 ,  G01N33/53 ,  G01N33/574

Abstract: The invention relates to methods for treating cancers by targeting the elimination of selective activated immune cell populations in combination with checkpoint inhibitors. The cells may be targeted, for instance, using CLIP inhibitors and or MHC class II inducers.

公开(公告)号：US20220347180A1

公开(公告)日：2022-11-03

申请号：US17764043

申请日：2020-09-25

Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE

Inventor： Yiqun Shellman ,  Richard Tobin ,  Nabanita Mukherjee ,  David Norris ,  Martin D.` Carter

IPC: A61K31/519 ,  A61K39/395 ,  A61K31/635 ,  A61P35/00

Abstract: Disclosed herein are methods for using therapeutic compounds, for example BH3 mimetics such as MCL1 inhibitors, to treat patients that may have failed to respond to targeted or immunotherapy treatments. In several embodiments, methods for treating such patients include combining MCL1 inhibitors with immunotherapies to enhance immunotherapy treatment. For example, the combination of MCL1 inhibitors with immunotherapies is used to treat cancer, such as melanoma. In some embodiments, MCL1 inhibitory compounds and therapies may be useful in treating tissues or tumors having one or more MDSC cell expressing high levels of MCL1. In some embodiments, MCL1 and BCL2 inhibitory compounds and therapies comprising same may be used to treat one or more melanomas, for example cutaneous melanoma, melanoma subtypes selected from uveal, acral, and mucosal. In some embodiments, MCL1 inhibitory compounds and therapies comprising same may be used to treat one or more melanomas, for example uveal melanoma. In many embodiments the targeted cells or tissues may not have BRAF mutations.

公开(公告)号：US20200268831A1

公开(公告)日：2020-08-27

申请号：US16646391

申请日：2018-09-14

Applicant: The Texas A&M University System ,  The Regents of the University of Colorado, a Body Corporate

Inventor： Richard Tobin ,  Martha Karen Newell-Rogers

IPC: A61K38/08 ,  A61P35/00 ,  G01N33/53 ,  G01N33/574 ,  C07K16/28

Abstract: The invention relates to methods for treating cancers by targeting the elimination of selective activated immune cell populations in combination with checkpoint inhibitors. The cells may be targeted, for instance, using CLIP inhibitors and or MHC class II inducers.